ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > APP

APP

概要

Name:Beta amyloid A4 protein
Target Synonym:Beta-CTF,Amyloid Beta Precursor Protein,Cerebral Vascular Amyloid Peptide,Beta-Amyloid Precursor Protein,Amyloid-Beta A4 Protein,Beta-Amyloid Peptide,Alzheimer Disease,CTFgamma,ABETA,AAA,PN2,Amyloid beta-Peptides,Amyloid intracellular domain 57,APP,Amyloid intracellular domain 59,PN-II,Alpha-secretase C-terminal fragment,AICD-50,S-APP-alpha,A4,S-APP-beta,Alzheimer disease amyloid protein,Abeta40,Gamma-CTF(59),Abeta42,Gamma-CTF(57),Alpha-CTF,Amyloid intracellular domain 50,AID(59),Gamma-CTF(50),A
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:44
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
CHEK-ATP081 Human HEK293/Human APP (GFP) Stable Cell Line
APP-H51H7 Human Human APP / Abeta40 Protein, His Tag
APP-H51H7-structure
APP-H51H7-sds
APP-H52H5 Human Human APP / SAPPbeta Protein, His Tag (MALS verified)
APP-H52H5-structure
APP-H52H5-sds
APP-M52H3 Mouse Mouse APP / N-APP Protein, His Tag (MALS verified)
APP-M52H3-structure
APP-M52H3-sds
ACRO Quality

生物活性データの一部

CHEK-ATP081-Cell-based assay
APP FACS

FACS analysis of APP (GFP) on HEK293/Human APP (GFP) Stable Cell Line.
HEK293/Human APP (GFP) Stable Cell Line was red line, negative control HEK293 cells was grey line (QC tested).

Protocol
APP-H52H5-MALS-HPLC
Human SAPPbeta, His Tag (Cat. No. ) MALS images

The purity of Human SAPPbeta, His Tag (Cat. No. APP-H52H5) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.

Report
  • Background
    Amyloid precursor protein (APP) is a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. It has three predominant splice variants: APP695, APP751, and APP770. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway. The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C99, which is subsequently cleaved by γ-secretase to release Aβ.
  • Clinical and Translational Updates
      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    APP-M52H3-MALS-HPLC
    Mouse N-APP, His Tag (Cat. No. ) MALS images

    The purity of Mouse N-APP, His Tag (Cat. No. APP-M52H3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.

    Report

Synonym Name

ABPP,APPI,Amyloid-beta A4 protein

Background

Amyloid precursor protein (APP) is  a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. It has three predominant splice variants: APP695, APP751, and APP770. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway.  The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C99, which is subsequently cleaved by γ-secretase to release Aβ.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Immune Globulin Subcutaneous (Human) (Octapharma) Approved Octapharma Cutaquig, Octanorm, Gammanorm United States Immunologic Deficiency Syndromes null 2018-08-02 Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes Details
L-Lysine hydrochloride/Cyanocobalamin/Inositol Approved 兴邦 Malnutrition Details
Lecanemab BAN-2401 Approved Bioarctic Neuroscience Leqembi, 乐意保, LEQEMBI United States Alzheimer Disease Eisai Inc 2023-01-06 Alzheimer Disease; Cognitive Dysfunction; Dementia Details
Sodium Oligomannurarate GV-971; 971 Approved Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 九期一 Mainland China Alzheimer Disease Shanghai Greenvalley Pharmaceutical Co Ltd 2019-11-02 Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease Details
Immune globulin 10% (Grifols) KIg-10; TAL-05-0002 Approved Bayer AG Gamunex, Gammaked United States Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes null 2003-08-27 Anxiety Disorders; Corneal Neovascularization; Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Common Variable Immunodeficiency; Neuralgia; Obsessive-Compulsive Disorder; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Autoimmune Diseases; Postural Orthostatic Tachycardia Syndrome; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Tibial Fractures; Myasthenia Gravis; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Details
Aducanumab BIIB-037; NI-10; BART Approved Neurimmune Ag, Eisai Co Ltd ADUHELM United States Alzheimer Disease Biogen Inc 2021-06-07 Dementia; Cognitive Dysfunction; Alzheimer Disease Details
Florapronol (18F) 18F-FC-119S; 18F-FC-119(S) Approved Korea Institute Of Radiological And Medical Sciences, Futurechem Alzavue Alzheimer Disease Details
Florbetaben (18F) MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI Approved Piramal Neuraceq, 欧韦宁 EU Alzheimer Disease Life Radiopharma Berlin Gmbh 2014-02-20 Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Alzheimer Disease; Amyloidosis; Dementia Details
Florbetapir(18F) MNI-798; AV-45 Approved Eli Lilly And Company Amyvid United States Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Eye Diseases; Collagen Diseases; Skin Diseases; Hypersensitivity Avid Radiopharmaceuticals Inc 2012-04-06 Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Lewy Body Disease; Diagnostic agents; Parkinson Disease; Respiration Disorders; Alzheimer Disease; Rheumatic Diseases; Cognitive Dysfunction; Contrast agents; Spasms, Infantile; Skin Diseases; Multiple Sclerosis; Glioblastoma Details
Flutemetamol (18F) AH-110690; GE-067; 18F-GE067 Approved Ge Healthcare Vizamyl United States Contrast agents Ge Healthcare 2013-10-25 Atherosclerosis; Cardiomyopathies; Breast Neoplasms; Contrast agents; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders Details
Inositol 4L6452S749 Approved Nicosit Anovulation; Depression; Anxiety; Polycystic Ovary Syndrome; Glucose Intolerance; Insulin Resistance; Diabetic Neuropathies; Infant, Newborn, Diseases; Bronchopulmonary Dysplasia; Metabolic Diseases; Lung Neoplasms; Retinopathy of Prematurity; Infant, Premature, Diseases; Carcinoma, Non-Small-Cell Lung; Hyperandrogenism; Precancerous Conditions Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Tarenflurbil spraygel (MIKA Pharma) Clinical Galen Ltd, Mika Pharma Gmbh Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic Details
AMDX-2011P AMDX-2011P; AMDX2011P Phase 2 Clinical Amydis Inc Cerebral Amyloid Angiopathy; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
Edonerpic T-817 MA Phase 2 Clinical Toyama Chemical Co Ltd, Fujifilm Group Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency Details
Buntanetap ANVS-405; ANVS-401 Phase 3 Clinical Raptor Pharmaceutical Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia Details
OAB-14 OAB-14 Phase 1 Clinical Shenyang Pharmaceutical University Alzheimer Disease Details
Remternetug LY-3372993 Phase 3 Clinical Eli Lilly And Company Alzheimer Disease Details
ALN-APP Phase 1 Clinical Sirna Therapeutics Inc Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases Details
RP-902 RP902; RP-902 Phase 1 Clinical Alzheimer Disease Details
Pittsburgh Compound B [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB Phase 2 Clinical The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease Details
[18F]THK-5105 [18F]THK-5105 Phase 2 Clinical Tohoku University Alzheimer Disease Details
RIV-1061-IR RIV-1061; RIV-1061-IR Phase 1 Clinical Revivo Therapeutics Alzheimer Disease; Cognition Disorders Details
11C-BF-227 11C-BF-227; [11C]BF-227 Phase 2 Clinical Tohoku University Diagnostic agents Details
PRI-002 RD-2; PRI-002 Phase 2 Clinical Priavoid Cognitive Dysfunction; Alzheimer Disease Details
NPT-088 NPT-088; NPT088 Phase 1 Clinical Proclara Biosciences Inc Alzheimer Disease Details
Abeta42 antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Alzheimer Disease Details
ABvac-40 ABvac-40 Phase 2 Clinical Araclon Biotech Sl Alzheimer Disease; Cognitive Dysfunction Details
ASN-120290 ASN-561; ASN-90; ASN-120290 Phase 1 Clinical Merck Serono Alzheimer Disease; Parkinson Disease Details
Crenezumab R-7412; RG-7412; RO-5490245; MABT-5102-A Phase 2 Clinical Ac Immune Sa, Genentech Inc Alzheimer Disease Details
Solanezumab LY-2062430 Phase 3 Clinical Eli Lilly And Company Alzheimer Disease; Dementia; Cognition Disorders Details
AD-35 AD-35 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Alzheimer Disease Details
[18F]THK-5117 [18F]THK-5117 Phase 2 Clinical Tohoku University Alzheimer Disease Details
L-clausenamide Phase 2 Clinical Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd Dementia; Cognitive Dysfunction; Memory Disorders Details
Valiltramiprosate NRM-8499; ALZ-801; BLU-8499 Phase 3 Clinical Alzheon Inc Alzheimer Disease Details
RQ-9 AAT-009; RQ-9; RQ-00000009 Phase 1 Clinical Pfizer Inc Dementia Details
NPT-189 NPT-189 Phase 1 Clinical Proclara Biosciences Inc Amyloidosis Details
APH-1105 APH-1105 Phase 2 Clinical Aphios Dementia; Alzheimer Disease Details
ALZ-101 ALZ-101 Phase 1 Clinical Alzinova AB Alzheimer Disease; Dementia Details
Inositol/Vitamin B1/Vitamin B2 Details
Birtamimab NEOD-001 Phase 3 Clinical Prothena Immunoglobulin Light-chain Amyloidosis; Amyloidosis Details
Trontinemab RO-7126209; RG-6102 Phase 2 Clinical F. Hoffmann-La Roche Ltd Alzheimer Disease Details
ID-1201 ID-1201 Phase 2 Clinical Ildong Pharmaceutical Co Ltd Alzheimer Disease Details
CT-1812 CT-1812; SV-119 Phase 2 Clinical Cogrx Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration Details
BEY-2153 BEY-2153 Phase 1 Clinical Beyondbio Inc Alzheimer Disease Details
18F-92 18F-92 Phase 2 Clinical First Affiliated Hospital Of Fujian Medical University Alzheimer Disease Details
Procaine Hydrochloride/Vitamin B6/Inositol Details
PMN-310 huPMN-310; PMN-310 Phase 1 Clinical ProMIS Neurosciences Inc Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy Details
A ß antibody Fab Phase 1 Clinical Eli Lilly And Company Alzheimer Disease Details
SHR-1707 SHR-1707 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Alzheimer Disease Details
Anatabine citrate RCP-006 Clinical Rock Creek, Roskamp Institute Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation Details
AV-1959D AV 1959D; AV-1959D Phase 1 Clinical Institute For Molecular Medicine, University Of California, Flinders University Alzheimer Disease Details
Gantenerumab MAb-31; R-1450; RG-1450; R-04909832 Phase 3 Clinical Chugai Pharmaceutical Co Ltd Alzheimer Disease; Dementia Details
123I-ABC-577 123I-ABC-577 Clinical Nihon Medi-Physics Co Ltd Diagnostic agents Details
PRX-012 PRX-012 Phase 1 Clinical Prothena Alzheimer Disease Details
ACU-193 ACU-193; ACU193 Phase 1 Clinical Acumen Pharmaceuticals Inc Alzheimer Disease Details
MDR-1339 DBT-1339; MDR-1339 Phase 1 Clinical Medifron Alzheimer Disease Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap